[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2008002243A1 - Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer. - Google Patents

Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.

Info

Publication number
CL2008002243A1
CL2008002243A1 CL2008002243A CL2008002243A CL2008002243A1 CL 2008002243 A1 CL2008002243 A1 CL 2008002243A1 CL 2008002243 A CL2008002243 A CL 2008002243A CL 2008002243 A CL2008002243 A CL 2008002243A CL 2008002243 A1 CL2008002243 A1 CL 2008002243A1
Authority
CL
Chile
Prior art keywords
pyrazolamino
triazine
cancer
treatment
pharmaceutical composition
Prior art date
Application number
CL2008002243A
Other languages
Spanish (es)
Inventor
Stephanos Ioannidis
Lynsie Almeida
Michelle Lamb
Bo Peng
Huiping Guan
Shi
Brian Quila
Claudio Edmundo Chuaqui
Shan Huang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008002243A1 publication Critical patent/CL2008002243A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparación; composición farmacéutica; y uso para el tratamiento del cáncer.Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.

CL2008002243A 2007-07-31 2008-07-30 Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer. CL2008002243A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95315807P 2007-07-31 2007-07-31

Publications (1)

Publication Number Publication Date
CL2008002243A1 true CL2008002243A1 (en) 2009-08-21

Family

ID=40304964

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002243A CL2008002243A1 (en) 2007-07-31 2008-07-30 Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.

Country Status (6)

Country Link
AR (1) AR069899A1 (en)
CL (1) CL2008002243A1 (en)
PE (1) PE20090895A1 (en)
TW (1) TW200906818A (en)
UY (1) UY31254A1 (en)
WO (1) WO2009016410A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (en) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 For the method and composition of cell Proliferation associated disease
CN102573485B (en) * 2009-06-08 2014-11-26 加利福尼亚资本权益有限责任公司 Triazine derivatives and their therapeutical applications
EP2440053A4 (en) * 2009-06-09 2012-10-31 California Capital Equity Llc Benzyl substituted triazine derivatives and their therapeutical applications
IN2012DN00471A (en) 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
ES2970938T3 (en) 2011-05-03 2024-05-31 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091858A1 (en) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc CISTATIONIN-g-LIASA INHIBITORS (CSE)
AU2013331626B2 (en) 2012-10-15 2018-08-02 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (en) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 2,4- the or 4,6- diaminopyrimidine compounds as IDH2 mutant inhibitor for treating cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105517996B (en) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 Therapeutical active compound and its application method
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20220070066A (en) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. Pharmaceutical compositions of therapeutically active compounds
US10150731B2 (en) 2015-01-16 2018-12-11 Bayer Cropscience Aktiengesellschaft Method for preparing 4-cyanopiperidine hydrochloride
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
UA123400C2 (en) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Combination therapy for treating malignancies
HUE067449T2 (en) 2015-10-15 2024-10-28 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103624A1 (en) * 2018-06-22 2019-12-26 Aduro Biotech, Inc. Triazine compounds and uses thereof
CN109020951B (en) * 2018-08-24 2020-06-02 大连理工大学 Naphthalimide derivative containing trisubstituted cyanuric chloride and synthesis method and application thereof
CN111454214B (en) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 Synthetic method of 2-methoxy-1-pyrimidineethylamine hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154747A0 (en) * 2000-09-15 2003-10-31 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
CA2432303C (en) * 2000-12-21 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2003225800A1 (en) * 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
PL1945631T3 (en) * 2005-10-28 2012-12-31 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
WO2009016410A3 (en) 2009-07-02
AR069899A1 (en) 2010-03-03
PE20090895A1 (en) 2009-08-08
WO2009016410A2 (en) 2009-02-05
TW200906818A (en) 2009-02-16
UY31254A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CL2008002243A1 (en) Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.
CL2009001274A1 (en) Substituted triazine-derived compounds, mediated by inhibition of p13 and mtor kinase; pharmaceutical composition; preparation procedure; and its use in the treatment of different types of cancer.
CL2008002097A1 (en) Compounds derived from substituted fused heterocycles, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition; and use in the treatment of cancer.
CL2011002942A1 (en) Compounds derived from 2,4-diamino-pyrimidine, toll-7 (tlr7) receptor agonists; pharmaceutical composition; and its use for the treatment of cancer.
CL2009000483A1 (en) Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
CL2008000020A1 (en) Compounds derived from substituted 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and malignant tumors.
CL2012003503A1 (en) Compounds derived from substituted morpholin pyrimidines, protein kinase atr inhibitors; Pharmaceutical composition, useful for the prevention or treatment of cancer tumors.
CL2008000021A1 (en) Compounds derived from 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and cancer.
CL2008001743A1 (en) Use of a compound derived from quinazoline to treat cancer; use of the compound and another antineoplastic compound; quinazoline derived compounds; and pharmaceutical composition comprising them.
CL2007003495A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED CONDENSED HETEROCICLES, INHIBITORS OF THE ACTIVITY OF THE AKT; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF CANCER.
CL2008002129A1 (en) Compounds derived from substituted (1h-indazol-3-yl) -amides, kinase inhibitors; pharmaceutical composition; preparation procedure; and use of the compound for the treatment of cancer.
CL2012000163A1 (en) Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others.
CL2011000191A1 (en) Compounds derived from substituted fused pyrimidine, mtor inhibitors; pharmaceutical composition that includes it; and use in the treatment of cancer.
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CL2007003756A1 (en) COMPOUNDS DERIVED FROM PIRAZOLO-QUINAZOLINA SUBSTITUTED, MODULATORS OF THE ACTIVITY OF PROTEIN KINASES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER.
CL2012003680A1 (en) Compounds derived from (1,8) 2,4 diaryl naphthyridines substituted kinase inhibitors; its procedure for obtaining; pharmaceutical composition; and its use for the treatment and / or prevention of cancer, tumor, malignant tumors, among others; Pharmaceutical kit
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2008000946A1 (en) COMPOUNDS DERIVED FROM PIRROLOPIRIMIDINA, INHIBITORS OF CIANASA JAK3; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF REPLACEMENT OF TRANSPLANTS, AUTOIMMUN DISEASES
CL2011000489A1 (en) Compounds derived from pyrimido [5,4-d] pyrimidine, which act as tyrosine kinase inhibitors; and pharmaceutical compositions that comprise them, useful in the treatment of diseases characterized by excessive or abnormal cell proliferation
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
CL2011001215A1 (en) Compounds derived from pyrimidine, tyrosine kinase inhibitors; pharmaceutical compositions comprising them; and its use in the treatment and / or prevention of cancer, inflammatory diseases and autoimmune diseases.
CL2008001705A1 (en) Compounds derived from nitrogen heterocycles; and use of the compound for the treatment of histamine h3 receptor related diseases or disorders.
CL2011001536A1 (en) Compounds derived from pyrimidin-2-yl-1h-indole, atr protein kinase inhibitors; pharmaceutical composition comprising one of the compounds; and use of the compounds in the preparation of useful medicines for the treatment of cancer.
CL2014001547A1 (en) Compounds derived from benzothienyl-pyrrolotriazine, such as protein tyrosine kinase inhibitors; preparation process of said compounds; pharmaceutical composition that includes them; and its use for the treatment and / or prevention of cancer and tumor diseases.